In Vivo Dosimetry for Brachytherapy Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Prostate Cancer, Gynaecological Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Single-centre Feasibility Study Investigating the Use of in Vivo Dosimetry in Patients Receiving High Dose Rate (HDR) Brachytherapy for Gynaecological and Prostate Cancers
Overview
The main study aim is the investigate the clinical use of in vivo dosimeters (small measurement devices) for brachytherapy (internal radiotherapy).
Detailed description
A dosimeter is a small device that is able to record the dose of radiation received. It can provide an independent check that the dose of radiation delivered matches the dose calculated for patients receiving radiotherapy as part of their cancer treatment.
The purpose of this study is to investigate the clinical use of in vivo dosimeters for brachytherapy. Two types of dosimeters will be used; micro metal oxide field effect transistors (microMOSFETs) and Thermoluminescent detectors (TLDs). These will be placed into the rectum (back passage), urethra (the tube through which urine leave the body from the bladder) and within or near (typically within a few centimetres) to the cancer itself. These devices will record the dose of radiation received at the time of brachytherapy at each of these sites and we will compare that measurement with the expected measurement based on the calculations we made in planning the patient's treatment.
Primary outcome measures
- To assess the feasibility of in vivo dosimetry in HDR brachytherapy and compare the calculated dose against measured dose [Time frame: 12 months]
Secondary outcome measures (1)
- Review of investigative and corrective action [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Patients aged 18 years and above
- Patients receiving HDR brachytherapy using iridium-192 (192Ir) radioactive source either as a monotherapy or in combination with external beam radiotherapy for:
- histologically/radiologically proven primary or locally recurrent prostate cancer
- locally advanced gynaecological malignancy in the primary and recurrent setting
- primary cervix carcinoma (squamous, adenocarcinoma, adenosquamous) FIGO IB2-IVA
- primary vulval FIGO I-IVA
- primary vaginal FIGO I-IVA
- primary endometrial cancer FIGO Stage I-IVA (not suitable for surgery)
- endometrial cancer receiving adjuvant vaginal vault brachytherapy
- recurrent cervix, vulval, vaginal or endometrial cancer suitable for brachytherapy as discussed in a regional gynae-oncology multidisciplinary meeting.
- World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Exclusion criteria
- Previous brachytherapy exposure to the treatment site
- Patients unable to give informed consent
- Patients unable to have a regional or general anaesthetic
- Patients with the following medical conditions: coagulopathies, history of another primary malignancy, known allergy or sensitivity to study materials; previous or current fistulae
- Not able to understand the implications of participating in the study in English
- Patients with recent (within the last 6 months) or currently participating in interventional research
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United Kingdom · 1 center
- Mount Vernon Cancer Centre — Northwood
Identifiers
NCT: NCT06863090 · RD2024-15